177 related articles for article (PubMed ID: 17427111)
1. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
Müssig K; Gallwitz B; Honegger J; Strasburger CJ; Bidlingmaier M; Machicao F; Bornemann A; Ranke MB; Häring HU; Petersenn S
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):198-202. PubMed ID: 17427111
[TBL] [Abstract][Full Text] [Related]
2. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
3. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.
Bergamaschi S; Ronchi CL; Giavoli C; Ferrante E; Verrua E; Ferrari DI; Lania A; Rusconi R; Spada A; Beck-Peccoz P
Horm Res Paediatr; 2010; 73(1):74-9. PubMed ID: 20190543
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
5. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
[TBL] [Abstract][Full Text] [Related]
6. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma.
Maheshwari HG; Prezant TR; Herman-Bonert V; Shahinian H; Kovacs K; Melmed S
J Clin Endocrinol Metab; 2000 Sep; 85(9):3409-16. PubMed ID: 10999842
[TBL] [Abstract][Full Text] [Related]
7. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
9. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation.
Zimmerman D; Young WF; Ebersold MJ; Scheithauer BW; Kovacs K; Horvath E; Whitaker MD; Eberhardt NL; Downs TR; Frohman LA
J Clin Endocrinol Metab; 1993 Jan; 76(1):216-22. PubMed ID: 8421089
[TBL] [Abstract][Full Text] [Related]
10. Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant.
Joshi K; Daly AF; Beckers A; Zacharin M
Horm Res Paediatr; 2018; 90(3):196-202. PubMed ID: 29953972
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening.
Mangupli R; Rostomyan L; Castermans E; Caberg JH; Camperos P; Krivoy J; Cuauro E; Bours V; Daly AF; Beckers A
Pituitary; 2016 Oct; 19(5):507-14. PubMed ID: 27287035
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant.
Goldenberg N; Racine MS; Thomas P; Degnan B; Chandler W; Barkan A
J Clin Endocrinol Metab; 2008 Aug; 93(8):2953-6. PubMed ID: 18492755
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
Saveanu A; Lavaque E; Gunz G; Barlier A; Kim S; Taylor JE; Culler MD; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2002 Dec; 87(12):5545-52. PubMed ID: 12466351
[TBL] [Abstract][Full Text] [Related]
14. An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant.
Meas T; Sobngwi E; Vexiau P; Boudou P
Ann Endocrinol (Paris); 2006 Jun; 67(3):249-52. PubMed ID: 16840917
[TBL] [Abstract][Full Text] [Related]
15. Pituitary gigantism: a retrospective case series.
Creo AL; Lteif AN
J Pediatr Endocrinol Metab; 2016 May; 29(5):597-602. PubMed ID: 26887033
[TBL] [Abstract][Full Text] [Related]
16. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
17. Management of type 2 diabetes mellitus associated with pituitary gigantism.
Ali O; Banerjee S; Kelly DF; Lee PD
Pituitary; 2007; 10(4):359-64. PubMed ID: 17629784
[TBL] [Abstract][Full Text] [Related]
18. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
20. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
